Aravive to Participate in Upcoming Virtual Investor Conferences in March
02 mars 2021 07h00 HE
|
Aravive, Inc.
HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
16 févr. 2021 07h00 HE
|
Aravive, Inc.
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a...
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
04 janv. 2021 16h05 HE
|
Aravive, Inc.
HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the...
Aravive Announces Board Member Transition to Advisory Role
31 déc. 2020 19h00 HE
|
Aravive, Inc.
HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be...
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
19 nov. 2020 07h00 HE
|
Aravive, Inc.
HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance...
Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
16 nov. 2020 16h05 HE
|
Aravive, Inc.
HOUSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present and...
Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020
10 nov. 2020 16h05 HE
|
Aravive, Inc.
HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual...
Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
10 nov. 2020 07h00 HE
|
Aravive, Inc.
Aravive to Receive $12 Million Signing Payment, up to an Additional $207 Million in Future Milestone Payments plus Tiered Royalties 3D Medicines to Lead Clinical Development and Commercialization of...
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
05 nov. 2020 16h05 HE
|
Aravive, Inc.
Company expects to initiate pivotal trial of AVB-500 in Platinum Resistant Ovarian Cancer during fourth quarter 2020/first quarter 2021, based on Phase 1b resultsOn-track to initiate Phase 1b/2 trial...
Aravive Appoints Michael W. Rogers to Board of Directors
17 sept. 2020 07h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that Michael W. Rogers...